zurück

Capmatinib (non-small cell lung cancer (NSCLC), pretreated patients with mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping)

 

Subject:

  • Active Sustance: Capmatinib
  • Name: Tabrecta®
  • Therapeutic area: Non-small cell lung cancer (NSCLC)
  • Pharmaceutical company: Novartis Pharma GmbH

 

Time table:

  • Start: 15.08.2022
  • Publication of assessment: 15.11.2022
  • End of public hearing: 06.12.2022
  • Final decision by G-BA: beginning of February 2023

 

Comparative therapy:

  1. Patients after first-line therapy with a PD-1/PD-L1 antibody as monotherapy:
    - Cisplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology) OR
    - carboplatin in combination with a third-generation cytostatic (vinorelbine or gemcitabine or docetaxel or paclitaxel or pemetrexed (except for predominantly squamous histology) OR
    - carboplatin in combination with nab-paclitaxel OR
    - monotherapy with gemcitabine or vinorelbine (only for patients with ECOG performance status 2 as an alternative to platinum-based combination treatment)
  2. Patients after first-line therapy with platinum-containing therapy: 
    - Docetaxel (only for patients with PD-L1 negative tumors) OR
    - pemetrexed (only for patients with PD-L1 negative tumors and except in cases of predominantly squamous histology) OR
    - nivolumab
    - pembrolizumab (only for patients with PD-L1 expressing tumors, tumor proportion score (TPS) ≥ 1%) OR
    - atezolizumab OR
    - docetaxel in combination with nintedanib (only for patients with PD-L1 negative tumors and adenocarcinoma histology)
  3. Patients after first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-containing therapy: 
    Patient-individual therapy depending on prior therapy and histology choosing from afatinib, pemetrexed, erlotinib, docetaxel, docetaxel in combination with ramucirumab, and docetaxel in combination with nintedanib and vinorelbine.